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Available online 12 May 2013Abstract Liposarcomas are tumors arising in white adipose tissue (WAT) with avidity for local recurrence. Aggressive
dedifferentiated liposarcomas (DDLS) may arise fromwell-differentiated subtypes (WDLS) upon disease progression, however, this
key issue is unresolved due in large part to knowledge gaps about liposarcoma cellular composition. Here, we wished to improve
insights into liposarcoma cellular hierarchy. Tumor section analysis indicated that the populations, distinguishable based on the
expression of CD34 (a marker of adipocyte progenitors) and CD36 (a marker of adipocyte differentiation), occupy distinct
intra-tumoral locations in bothWDLS and DDLS. Taking advantage of thesemarkers, we separated cells from a panel of fresh human
surgical specimens by fluorescence-activated cell sorting (FACS). Based on chromosome analysis and the culture phenotypes of the
composing populations, we demonstrate that malignant cells comprise four mesenchymal populations distinguished by the
expression of CD34 and CD36, while vascular (CD31+) and hematopoietic (CD45+) components are non-neoplastic. Finally, we show
that mouse xenografts are derivable from both CD36-negative and CD36-positive DDLS cells, and that each population recreates
the heterogeneity of CD36 expression in vivo. Combined, our results show that malignant cells in WDLS and DDLS can be classified
according to distinct stages of adipogenesis and indicate immunophenotypic plasticity of malignant liposarcoma cells.
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Sarcomas, cancers of connective tissues, are diagnosed in
approximately 10,000 U.S. patients annually with a five-year
survival rate of only 50% (Anaya et al., 2009). Liposarcomas,
including well-differentiated (WDLS), dedifferentiated (DDLS),
pleomorphic, andmyxoid variants, arise in white adipose tissue
(WAT) and are among the deadliest of these tumors (Kooby
773Complexity of human liposarcomaset al., 2004; Lahat et al., 2008). WDLS are more common and
characterized by repetitive local recurrence with minimal risk
of metastasis. In contrast, DDLS are aggressive malignancies
with the capacity for distant spread and lethal outcome
even after an initial successful treatment (Kooby et al.,
2004; Gilbert et al., 2009). Malignant cells within WDLS and
DDLS typically demonstrate amplification of chromosome 12
(12q13–15) the locus ofMDM2, CDK4 and SAS genes (Weaver et
al., 2009). The liposarcoma cell type in which genetic changes
first occur is unknown. It is also unclear if WDLS is the
predecessor of DDLS or whether these two subtypes, often
found within the same tumor, arise independently. To date,
the characterization of liposarcoma cells has only been
performed following expansion in culture (Peng et al., 2011).
Lack of information on the in vivo cellular liposarcoma
hierarchy has hampered the understanding of the mechanisms
underlying the disease progression.
Investigation of many solid cancers has been facilitated by
classifying constituent malignant cells into distinct populations
corresponding to the differentiation stages of benign tissue
counterparts (Matsui et al., 2004; Tang, 2012). In response toA
B
Figure 1 WDLS and DDLS cells at distinct differentiation stages
surface markers used for liposarcoma cell classification, during
(B) Immunolocalization of distinct liposarcoma populations in seri
subjected to immunofluorescence with antibodies against CD36 or
adjacent stromal CD36+CD34+ cells (arrowheads) and mainly peri
non-malignant vasculature expressing CD31 (green). Nuclei are bluemetabolic imbalance, WAT has a capacity to quickly grow in
mass, resulting in obesity (Daquinag et al., 2011a; Sun et al.,
2011). WAT expansion is as a result of proliferation and
differentiation of a progenitor population that is similar to
mesenchymal stromal/stem cells (MSC) initially described in
the bonemarrow (Prockop, 1997; Pittenger et al., 1999; Bianco
et al., 2008; Caplan and Correa, 2011). These adipose MSC,
termed adipose stromal cells (ASC), serve as progenitors of
preadipocytes (Rodeheffer et al., 2008; Tang et al., 2008),
ultimately differentiating into white adipocytes, which are
large cells accumulating triglycerides in lipid droplets and the
main cellular component of WAT (Cinti, 2011; Daquinag et al.,
2011a). In addition to ASC, WAT contains endothelial cells
and infiltrating leukocytes, which may also contribute to the
adipocyte pool in pathological conditions (Daquinag et al.,
2011b; Kolonin et al., 2012). Gene expression profiles
(Matushansky et al., 2008) and adipogenic potential of lipo-
sarcoma cells (Peng et al., 2011) have indicated the mesen-
chymal origin of liposarcomas, however the possibility of
hematopoietic or endothelial cells also undergoing malignant
transformation has not been ruled out.(A) A schematic depicting expression of CD34 and CD36, cell
the differentiation of mesenchymal adipocyte progenitors.
al paraffin sections of representative WDLS and DDLS samples
CD34 (red). CD36+CD34− cells with adipocyte morphology (*),
vascular CD36−CD34+ cells (arrows) are indicated relative to
. Scale bar: 50 μm.
774 Y. Zhang et al.We hypothesized that, by analogy with benign cells of
adipocyte lineage (Fig. 1A), malignant cells inWDLS and DDLS
could be classified as per distinct stages of adipogenesis. Our
studies identify four distinct mesenchymal populations of
malignant cells in both WDLS and DDLS and establish a
protocol by which they can be separated from non-malignant
(hematopoietic and endothelial) cells of tumor microenvi-
ronment. We show that a population of malignant cells in
both WDLS and DDLS has features of ASC, whereas other cell
populations have immunophenotypes corresponding to vari-
able degrees of adipocyte differentiation. Our experiments
in DDLS xenograft mouse models show that cell populations
separated based on distinct immunophenotypes have com-
parable tumor-initiation capacities and can re-generate the
distinct immunophenotypic populations in vivo.Materials and methods
Matched pathologically graded tumor samples were used for
immunohistological and flow cytometric analysis.Tissue section analysis
Analysis of formalin-fixed paraffin-embedded tissue sections
was performed as described (Klopp et al., 2012) after antigen
retrieval, washing with 0.2% Triton X-100, blocking in Serum-
Free Protein Block (DAKO), followed by incubation with primary
antibodies (4 °C, 12 h) and secondary antibodies (room tem-
perature, 1 h) in PBS containing 0.05% Tween 20. Primary
antibodies: PA1-16813 rabbit anti-CD36 (Pierce), SC-9095 rabbit
anti-CD34 (Santa Cruz), and SC-1506 goat anti-CD31 (Santa
Cruz). Secondary donkey IgG anti-goat Alexa 488-conjugated
was from Invitrogen; anti-rabbit Cy3-conjugated was from
Jackson ImmunoResearch. Manufacturer-recommended anti-
body concentrations were used. Nuclei were stained with
Hoechst 33258 (Invitrogen). Images were acquired with
Olympus IX70 inverted fluorescence microscope/MagnaFire
software.Cell phenotyping
Cell suspensions of surgically resected tissues were prepared
through collagenase/dispase digestion as described (Zhang
et al., 2009; Klopp et al., 2012). Fluorescence-activated
cell sorting (FACS) was performed with a FACSAria flow cyto-
meter and the FACSDiva software (BD Bioscience) as described
(Bellows et al., 2011a,b). Cells were gated to exclude cell
clumps, contaminating polymorphonuclear cells, red blood cells,
platelets, endothelial microparticles, debris, and dead cells
based on 7-AAD staining. Viable cells (N200,000 per sample)
were then used to enumerate individual populations. Antibodies
used along with appropriate isotype control IgGs: fluorescein
isothiocyanate-conjugated anti-CD31 (clone WM59, BD Biosci-
ence), phycoerythrin-conjugated anti-CD34 (clone 8G12, BD
Bioscience), allophycocyanin-Cy7-conjugated anti-CD45 (clone
HI30, BD Bioscience) and eFluor® 660-conjugated anti-CD36
(eBioNL07, eBioscience). Cells from the sorted populations were
immobilized by cytospins and FISH analysis for 12q15 amplifica-
tion was performed as described (Peng et al., 2011).Cell culture
Cells were cultured in DMEM containing 10% fetal bovine
serum, L-glutamine and penicillin/streptomycin. After 1 day,
non-adherent cells were removed by washing with phosphate-
buffered saline (PBS), and adherent cells were quantified and
analyzed. For expansion, cells were passaged using 0.25%
trypsin/0.1% EDTA at densities not exceeding 5000 cells/cm2.In vivo studies
As described previously (Peng et al., 2011), 6–8 week-old
NOD scid gamma (NSG) mice (Jackson Laboratory, USA) were
injected subcutaneously with indicated numbers of cells in
150 μl of PBS. Tumor size was measured with a caliper
and volume was calculated as length × width2 × 0.52. Once
tumors surpassed 1 cm3 in size, mice were euthanized and
tumors were resected.
Statistical analysis was performed with unpaired Student's t
test.Results
Heterogeneity of WDLS and DDLS cells revealed in
tumor sections
As markers for the analysis of liposarcoma cell heterogeneity,
we chose CD34, a single-pass type 1 transmembrane
sialomucin expressed in adipose and some other progenitor
cells (Daquinag et al., 2011b), and CD36, a scavenger receptor
that functions as a fatty acid transporter in adipocytes (Kampf
et al., 2007). Expression of both CD34 and CD36 has been
previously reported for liposarcomas (Mechtersheimer, 1991).
It has been shown that ASC express high levels of CD34 but low
levels of CD36 (Festy et al., 2005). During adipocyte dif-
ferentiation, the expression of CD34 decreases whereas the
expression of CD36 increases (Kampf et al., 2007), resulting in
preadipocytes with intermediate expression levels of these
molecules (Fig. 1A). In differentiated adipocytes, CD34 is not
expressed, whereas the expression of CD36 becomes promi-
nent, rendering them as CD34−CD36+.
To investigate the niches that distinct populations occupy
within the tumor, we immunolocalized cells expressing
CD36+ and CD34+ relative to endothelial cells expressing
CD31/PECAM-1 in human liposarcomas. Immunofluorescence
analysis of tumor sections revealed several distinct cell
types. Cells with the adipocyte morphology positive for CD36
and negative for CD34 were observed in both WDLS and DDLS
(Fig. 1B), and were predictably more abundant in WDLS.
Clusters of cells expressing both CD34 and CD36 were
frequently observed in the vicinity of differentiated adipo-
cytes and were equally common in both WDLS and DDLS
(Fig. 1B). This cell population likely represents partially
differentiated liposarcoma cells. Finally, a population of
CD34+CD36− cells was observed surrounding the vasculature
in both WDLS and DDLS (Fig. 1B). This immunophenotype and
this localization are characteristic of ASC, which are known
to serve as pericytes and adventitial cells in WAT (Traktuev
et al., 2008; Corselli et al., 2011).
775Complexity of human liposarcomasMalignant cells comprise the mesenchymal
liposarcoma population
For systematic analysis of human liposarcomas, we isolated
tumor cell suspensions from multiple WDLS and DDLS using
enzymatic tissue digestion. To initiate characterization of
the cellular hierarchy composing WDLS and DDLS, we
subjected freshly isolated tumor cells to flow cytometry.
First, we deemed it important to confirm that the malignant
liposarcoma cells are restricted to the mesenchymal line-
age. In analyzing several WDLS and DDLS cases, we observed
a large proportion of tumor cells as CD36+ or CD34+
(Fig. 2A). We subjected cytospins of the FACS-sorted cells
to fluorescence in situ hybridization (FISH), detecting 12q15
chromosomal segment amplification. This hallmark of
liposarcoma was observed for the majority of CD36+ (66%)
and CD34+ (74%) cells, indicating that cells at various stages
of differentiation are malignantly transformed (Fig. 2B). The
minor fraction of CD34+ cells lacking this amplification
apparently correspond to benign progenitors, previously
reported to infiltrate liposarcomas (Morozov et al., 2010).
We also performed FACS with antibodies to CD31 (not shown)
and pan-leukocyte marker CD45 (Fig. 2A). Consistent with
previous reports (Tseng et al., 2012), a significant fraction of
liposarcoma cells corresponded to vascular endothelial cells
and infiltrating leukocytes, some of which express variable
levels of CD34 and CD36. Importantly, we could not detect
12q15 amplification in these populations (Fig. 2B).
Consistent with our previous observations (Peng et al.,
2011), adherent cells were isolated from both WDLS and DDLS
cases based on conditions used to culture ASC (Zhang et al.,
2009; Daquinag et al., 2011a; Klopp et al., 2012; Zhang et al.,
2012). The majority of cells sorted as CD36+ had morphol-
ogies typical of preadipocytes and contained phase-bright
lipid droplets, indicating their partial differentiation
(Fig. 2C). In contrast, cells sorted as CD34+ did not contain
lipid droplets and had the appearance of mesenchymal
fibroblasts with defined nuclei and nucleoli (Fig. 2C), which
is typical ASC/MSC morphology as reported previously (Zhang
et al., 2009; Daquinag et al., 2011a; Klopp et al., 2012). Both
CD36+ and CD34+ cells had a high plating efficiency (N1/20).
In contrast, plating efficiency of the non-malignant CD45+
population was remarkably lower (1/340). The adherent
CD45+ cells had characteristic myelomonocytic morphologies
(Fig. 2C). Both CD34+ and CD36+ cells were highly prolifer-
ative and could be indefinitely passaged in standard MSC
maintenance conditions, as expected of malignant cells,
while CD45+ and CD31+ cells failed to proliferate. Combined,
these data indicate that liposarcoma-infiltrating hematopoi-
etic and endothelial cells are benign whereas counterpart
malignant cells are comprised by mesenchymal populations at
different stages of adipogenesis.Classification of malignant cell populations in WDLS
and DDLS
Next, we established a flow cytometric methodology to
separate distinct malignant liposarcoma populations. We
analyzed cells from a panel of human WDLS (N = 5) and DDLS
(N = 5) after double labeling with CD34 and CD36 antibodies.
Four distinct populations were observed: CD34dim/CD36dim (CD34dCD36d), CD34dim/CD36bright (CD34dCD36b),
CD34bright/CD36− (CD34bCD36−) and CD34bright/CD36+
(CD34bCD36+). According to the adipogenesis model
(Fig. 1A), the CD34dCD36b population contains adipocytes,
the CD34bCD36− population contains ASC, while the
CD34bCD36+ and CD34dCD36d populations contain partially
differentiated cells. As expected, a variably abundant
sub-population of cells negative for both CD34 and CD36 was
observed, which accounted for infiltrating non-malignant and
possibly a fraction of malignant cells (Fig. 2D). The four CD34/
CD36 populations were clearly defined in all analyzedWDLS and
DDLS samples, although absolute marker expression levels for a
respective population varied. Cell separation into the corre-
sponding four populations was also observed for benign WAT
resected from the patients (N = 5) during surgery (Fig. 2D).
Although the levels of CD34 and CD36 expression in the
respective populations of normal WAT and tumors were
variable, these data show that cells in liposarcomas maintain
the phenotypic diversity of parental WAT tissue. Quantifica-
tion of these sub-populations in different samples of WAT,
WDLS and DDLS (N = 5 each), revealed that the CD34bCD36−
cells are significantly more abundant in DDLS than in WDLS
and benign WAT (Fig. 2E). Importantly, we observed the
same trend when comparing the WDLS and DDLS components
of the same tumor (data not shown). These observations
suggest that malignant cells with the phenotype of adipose
mesenchymal progenitors are enriched during liposarcoma
progression. It should be noted that in both, WAT and tumors,
the differentiated CD34dCD36b fraction was underrepre-
sented because adipocytes mainly do not register in flow
cytometry due to their buoyancy, large size, and fragility.
For each population (CD34dCD36d, CD34dCD36b,
CD34bCD36− and CD34bCD36+), FISH analysis of cells sorted
from tumors revealed a high frequency of 12q15 amplifica-
tion, indicating them as malignant (Fig. 2F). Liposarcoma
cells negative for 12q15 amplification were observed as a
variable minor fraction of each population, accounting for
the contributing benign mesenchymal, hematopoietic, and
endothelial cells (Morozov et al., 2010). As revealed by flow
cytometric analysis (Supplemental Fig. 1), virtually all cells
in CD34bCD36+ and CD34bCD36− populations are negative
for CD45 and CD31, consistent with them being mesenchymal
malignant cells. About 5% of CD34bCD36+ cells express
CD31, indicating this sub-fraction being endothelial cells.
In CD34dCD36d and CD34dCD36b populations, a significant
sub-fraction of CD45+CD31− cells was observed, which ac-
counts for infiltrating leukocytes. These data are in agreement
with CD36 expression reported for sub-populations of leukocytes
and endothelial cells also observed in tissue sections (Fig. 1B).
We also analyzed the morphology of individual cell
populations upon plastic attachment in culture. Only scant
adherent cells could be isolated from the CD34dCD36b
sub-population (Fig. 2F), consistent with it containing endo-
thelial cells (some of which express CD36) and occasional
viable adipocytes, which are both poorly adherent. The
CD34dCD36d and CD34bCD36+ cells were mostly adherent
and contained lipid droplets, consistent with these sub-
populations corresponding to malignant preadipocyte-like
cells (Fig. 2F). Finally, the CD34bCD36− cells were lipid
droplet-free, consistent with this sub-population correspond-
ing to malignant ASC-like cells (Fig. 2F). Combined, these
observations reinforce our tumor section analysis data,
776 Y. Zhang et al.indicating that in bothWDLS and DDLSmalignant cells comprise
a heterogeneous hierarchy composed of cellular populations
undergoing varying degrees of adipogenic differentiation.A
B
C
D
E
FAnalysis of freshly isolated CD34/CD36 populations
revealed variable expression of CD73, CD90, and CD150,
the markers expressed by MSC and ASC (Bianco et al., 2008;
777Complexity of human liposarcomasBellows et al., 2011a). In WDLS, all four populations
contained a significant component of CD73+ and CD90+
cells, while cells with significant CD105 expression were not
observed (Supplemental Fig. 2A). Cells lacking MSC marker
expression, particularly prominent in the two CD34d popu-
lations, likely correspond to differentiating adipocytes, as
well as the endothelial and leukocyte populations detected
through the use of CD31 and CD45 (Supplemental Fig. 1) In
DDLS, the frequency of CD73+ and CD90+ cells in each of the
four populations was increased compared to WDLS, while
CD105 expression was still insignificant (Supplemental Fig.
2B). These data are consistent with the decreased extent of
adipocyte differentiation in progressed disease and with
enrichment for cells with the ASC properties detected
though the use of CD34 as a marker (Fig. 2D–E).Plasticity of liposarcoma populations in culture and
in mouse xenografts
Next we performed tumorigenicity studies in mouse xeno-
graft models. In our previous reports, we have successfully
established xenografts in immunodeficient mice via injection
of DDLS (but not WDLS) cells cultured for several passages
(Peng et al., 2011). While for many human cancers tumors
can grow in mice upon injection of only few malignant cells
(Matsui et al., 2004; Tang, 2012), for unclear reasons
liposarcoma cells are poorly tumorigenic in the xenograft
setting. Injection of as many as 8 × 106 unsorted freshly
isolated liposarcoma cells has not generated xenografts in all
immunodeficient host strains (Nude, SCID and NSG) that we
have tested. We have also injected up to 2 × 106 uncultured
cells separated by FACS from two different DDLS tumors.
Neither bulk tumor cells nor freshly sorted CD34dCD36d,
CD34dCD36b, CD34bCD36−, or CD34bCD36+ populations
generated xenografts, indicating that ex vivo cell passaging
is a requisite for liposarcoma xenograft take. We, therefore,
chose cells from a DDLS sample (termed Lipo863), shown to
express adipogenesis genes, accumulate lipid droplets upon
differentiation induction, and grow tumors in immunodefi-
cient mice (Peng et al., 2011) to perform the remainder of our
studies. Analysis of Lipo863 cells by flow cytometry indicated
that CD34 expression was lost in these cells in culture
(Fig. 3A), which is also typical of benign ASC (Gimble et al.,
2007). Expression of CD36 was also reduced compared to the
parental tumor; however, the cells were clearly separated
into two distinct populations (CD36− and CD36+) based on
the level of CD36 expression (Fig. 3A). Upon FACS, each
population, in culture, presented as adherent cells morpho-
logically similar to normal ASC (Fig. 3A). Both CD36− andFigure 2 Characterization of WDLS and DDLS populations (A) FACS
CD45 in a representative WDLS. Percentages of cells positive for a
malignant cells through the detection of the 12q15 amplification (r
sorted based on the expression of CD36, CD34, or CD45 from the W
were used. (D) FACS 3D contour graphs for representative samples o
Fig. 1 (B). Gates for CD34dCD36d, CD34dCD36b, CD34bCD36−, and C
analyzed in multiple samples were calculated for normal WAT,
population ± SD among viable tumor cells in are shown. * P b 0.05.
sample upon plastic adherence in culture. FISH detecting the 12
malignant. Green: centromeric probe; blue: DAPI. Scale bar: 50 μmCD36+ populations of cultured Lipo863 cells were found to
unanimously express CD73, CD90, as well as CD105 (Supple-
mental Fig. 3), confirming their similarity to ASC/MSC.
To test whether the expression of CD34 could be re-
created in vivo, we injected 106 Lipo863 cells into immuno-
deficient mice. Cell suspensions were prepared from resul-
tant tumor xenografts and analyzed by flow cytometry. Our
data show that both CD36− and CD36+ populations were
expanded in tumors; however, the CD34-positive populations
could not be regenerated (Fig. 3B). A population with weak
level of CD34 signal observed in Lipo863 xenografts (Fig. 3B)
has been identified as mouse leukocytes infiltrating the
tumor (data not shown). Analysis of tumor sections by
immunofluorescence confirmed heterogeneous expression
of CD36 and the general lack of CD34 expression in vivo
(Fig. 3C). These observations indicate that CD34 expression
is not a requisite for the tumorigenicity of liposarcoma
cells.
Examination of mouse Lipo863 tumor xenograft cells upon
adherence in culture did not reveal noticeable morphological
differences between populations sorted as CD36− and CD36+.
Both CD36− and CD36+ cells displayed comparable plating
efficiency and a phenotype typical of freshly isolated ASC
(Fig. 3B). To compare the tumor-initiating capacities of these
populations, we performed in vivo limiting dilution experiments
(Supplemental Fig. 4A). Both CD36− and C36+ populations
produced tumors by 12 weeks upon subcutaneous injection of as
few as 104 cells into host immunodeficient mice, while neither
population produced tumors upon the injection of 103 cells.
We also separately injected matched numbers of CD36−
and CD36+ cells freshly sorted from primary Lipo863
xenografts (Fig. 3B) into secondary recipients; mouse
leukocyte populations sorted from the primary xenografts
were injected as controls. After four weeks, we observed
growth of tumors derived from both CD36− and CD36+ cells
(Fig. 3D). Tumors reached maximal tolerable size at week 12
and were resected then (Fig. 3E). Analysis of the secondary
Lipo863 xenografts by flow cytometry demonstrated that in
vivo both CD36− and CD36+ cells regenerated the original
heterogeneity of Lipo863 cells. The two distinct populations
(CD36− and CD36+) were present in secondary transplants
initiated by either CD36− or CD36+ cells, as assessed by flow
cytometry (Fig. 4A). Analysis of tumor sections by immuno-
fluorescence also indicated comparable frequencies and
distribution patterns for CD36-expressing cells and compa-
rable levels of CD36 expression and morphology of these
cells (Fig. 4B). These observations indicate that tumor
formation capacity is not related to the expression of CD36
and reveal the immunophenotypic plasticity of populations
identified within liposarcomas.separation of cells based on the expression of CD36, CD34, and
marker among viable cells are indicated. (B) Identification of
ed) by FISH in CD36+ and CD34+ cells. (C) Morphology of cells
DLS tumor upon adherence. In (B–C), WDLS cells isolated in (A)
f benign WAT, as well as for WDLS and DDLS samples analyzed in
D34bCD36+ cells are shown. (E) Percentages among viable cells
WDLS and DDLS (N = 5 for each). Mean frequencies of each
(F) Morphology of cells sorted in (D) from a representative DDLS
q15 amplicon (red) confirms cells in the four populations as
.
AB
C
D E
Figure 3 Culture plasticity and tumorigenicity of liposarcoma cells. (A) Separation of early passage Lipo863 cells derived from a
representative DDLS sample (Fig. 2D) based on CD36 and CD34 expression (left) and morphology of sorted CD36+ and CD36− Lipo863
cells upon adherence (right). (B) Separation of cells derived from a Lipo863 mouse xenograft based on CD36 and CD34 expression
(left) and morphology of CD36+ and CD36− cells sorted from the mouse Lipo863 tumor upon adherence (right). (C) Paraffin sections of
xenografts grown from Lipo863 cells subjected to immunofluorescence with antibodies against CD36 or CD34 (red) and against CD31
(green). Arrows indicate CD36 expression. Nuclei are blue. Scale bar: 50 μm. (D) Tumor growth in mice xenografted with 106 cells of
the indicated Lipo863 (B) populations or with 106 tumor-infiltrating mouse leukocytes. (E) Photographs of indicated tumor-bearing
mice and resected tumors at week 12 post-grafting.
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C
Figure 4 Plasticity of liposarcoma populations in mouse xenografts. (A) Separation of cells from secondary xenografts of CD36+
(left) and CD36− (right) cells (Fig. 3D–E) into CD36+ and CD36− populations. (B) Paraffin sections of xenografts grown from CD36+
cells (left) and CD36− cells (right) subjected to immunofluorescence with antibodies against CD36 (red) indicating a comparable
distribution of CD36-expressing cells relative to vasculature expressing CD31 (green). Nuclei are blue. Scale bar: 50 μm. (C) A model
of liposarcomagenesis. Liposarcoma arises in benign WAT as a result of 12q13–15 amplification and MDM2 overexpression (red
nucleus), which occurs at one of the stages of adipogenesis (box). DDLS arise either from WDLS though gradual dedifferentiation of
progressive percentage of tumor cells to the ASC-like phenotype or independently of WDLS by separate mutations in WAT leading to a
comparatively more aggressive domination of malignant ASC-like cells.
779Complexity of human liposarcomasDiscussionThe relative rarity of liposarcomas has posed a challenge for
investigations of these lethal soft tissue cancers (Kooby et
al., 2004; Lahat et al., 2008; Anaya et al., 2009; Gilbert
et al., 2009). To begin characterization of their cellularorganization, we systematically analyzed multiple WDLS and
DDLS surgical specimens. Analysis of freshly isolated human
cells based on flow cytometry, FISH, and immunofluores-
cence microscopy of tissue sections has indicated that
malignant cells in both WDLS and DDLS comprise exclusively
mesenchymal populations at several distinct stages of
adipogenesis. Building on previous reports addressing CD34
780 Y. Zhang et al.and CD36 expression in liposarcomas (Mechtersheimer,
1991), our work provides new information on the distribution
of individual cell types distinguished through these markers
in WDLS and DDLS. Experiments with Lipo863, the adipogenic
DDLS cells with ASC morphology (Peng et al., 2011),
demonstrate CD34 and CD36 expression changes in lipo-
sarcoma cells upon ex vivo propagation. The capacity of each
distinct Lipo863 population identified based on CD36 expres-
sion to re-create the initial Lipo863 complexity in the mouse
xenograft model indicates immunophenotypic plasticity of
malignant liposarcoma cells. This phenomenon may reflect
the recently revealed plasticity of benign white adipocytes,
which are capable of de-differentiation and trans-
differentiation (Cinti, 2011).
Based on our combined data and the frequencies and
phenotypes of the individual populations isolated from
primary human tumors, we propose a hierarchical model of
liposarcoma progression (Fig. 4C). According to this model,
malignant transformation of one of the cell populations in
WAT, which involves 12q13–15 amplification and concomi-
tant molecular changes, leads to the formation of WDLS or
DDLS. We hypothesize that the expansion of the malignant
liposarcoma populations result in equilibrium of cell pheno-
types that differ by the status of differentiation, in which
distinct cell populations serve mutually beneficial roles. The
observed enrichment of malignant cells with the ASC
phenotype in DDLS compared to WDLS could be explained
by WDLS progressing to DDLS through progressive transfor-
mation of malignant ASC-like cells that eventually over
proliferate and dominate. However, it is equally possible
that critical additional mutations take place de novo, thus
leading to a more aggressive clone forming DDLS with
decreased capacity to differentiate. These non-exclusive
scenarios may both occur in the clinical context.
In hematological malignancies, cancer-initiating cells
have been identified as a population potentially represent-
ing a key clinical target (Matsui et al., 2004; Dick and
Lapidot, 2005; Gupta et al., 2009). This paradigm, now
extended to some solid cancers, is based on the concept that
a single immunophenotypic cell population can re-create the
diversity of cells in the original tumor upon xenotransplan-
tation (Reya et al., 2001; Tan et al., 2006; Tang, 2012).
Previously, ASC have been proposed as the origin of
liposarcomas (Gimble et al., 2007). A direct test of this
hypothesis is currently not technically feasible due to the
inability of cells sorted from freshly isolated tumors to
survive in immunodeficient mice for reasons that are not
clear. While additional studies will be necessary to establish
the etiology of liposarcomas, at this juncture our data
indicate that malignant populations similar to ASC are
indeed present in both WDLS and DDLS. Expression of MSC
markers by both tumorigenic Lipo836 populations confirms
that aggressive liposarcoma cells are ASC/MSC-like and
indicates that CD105 expression is induced in culture.
Compared to adenocarcinoma cells, both primary and
cultured liposarcoma cells showed low capacity to migrate,
invade matrix, and form soft agar colonies (Supplemental
Fig. 4) in assays performed as described (Peng et al., 2011).
Interestingly, primary cells with the ASC phenotype
(CD34bCD36−) sorted from DDLS displayed higher motility
than the other three populations (Supplemental Fig. 4C).
This migratory capacity, also observed for tumorigenicLipo863 cells, is consistent with the properties of ASC
(Zhang et al., 2009, 2012). Our data indicating the expres-
sion of ΔDCN, the recently described adipose progenitor
marker (Daquinag et al., 2011a), by Lipo863 cells and their
sensitivity to an experimental ΔDCN-targeting compound
(data not shown) support the resemblance between tumor-
igenic liposarcoma cells and benign adipose progenitors.
However, because in our experiments both less and more
differentiated cells formed tumors and recreated immuno-
phenotypic heterogeneity, our data does not indicate ASC
being the exclusive origin of ‘liposarcoma stem cells’.
Regardless of the tumor cell origin, similarity of the
aggressive liposarcoma fraction to ASC has potentially
important implications. It has been previously shown that
ASC are recruited by malignant lesions and become an
important component of the trophic microenvironment in
adenocarcinomas (Zhang et al., 2009; Kolonin et al., 2012;
Zhang et al., 2012). These supportive cells integrating into
tumor stromal and perivascular niches have paracrine
mitogenic and cytoprotective tumor-stimulating growth
effects. In addition, mesenchymal progenitors, suppressing
inflammation and muting the T cell-mediated response, may
be at least partially responsible for immune system evasion
by the tumor (Kolonin et al., 2012). Finally, MSC in general
(and ASC specifically) are resistant to hypoxia, chemotherapy,
and radiotherapy, and have been shown to have protective
effects on adjacent malignant cells (Bianco et al., 2008;
Caplan and Correa, 2011). This opens a possibility that the
ASC-like fraction of liposarcoma may not only serve as a
cancer-initiating population, but could also confer treatment
resistance to other cell populations within WDLS and DDLS.
Conclusions
In summary, our study provides new insights into the cell
hierarchy ofWDLS and DDLS and helps elucidate the remarkably
complex liposarcoma internal milieu. The results of this work
may improve our understanding of sarcomagenesis, leading to
new approaches to diagnosis, prognosis and treatment. The
uncovered plasticity of liposarcoma-initiating cells, previously
observed for other cancer types (Tang, 2012), is likely to
explain the challenges of pharmacological liposarcoma treat-
ment (Kooby et al., 2004; Lahat et al., 2008; Anaya et al., 2009;
Gilbert et al., 2009). Future studies will further dissect the
individual roles of the distinct cell types maintained in soft
tissue tumors and help generate improved reagents targeting
clinically important cell populations.
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